Asymmetric hydrogenation of a 4,4-diaryl-3-butenoate; a novel approach to sertraline.
The asymmetric hydrogenation of a selectively crystallised (E)-4,4-diaryl-3-butenoate with a rhodium-PhanePhos catalyst is described, providing an intermediate to the antidepressant sertraline.